Novartis Deutschland

Leading pharmaceutical innovation and research

About Novartis Deutschland

A leading pharmaceutical company focused on innovating medicine to enhance people's lives through scientific research and digital technologies

Goldman hebt Ziel für Novartis auf 113 Franken - 'Sell'
Goldman Sachs increased Novartis's price target to 113 francs but maintained a 'Sell' rating, with analyst estimates aligning with market consensus and future outlook comments being key.
de.marketscreener.com · Oct 1, 2026
Novartis-Analyse: Deutsche Bank AG stuft Aktie mit Hold ein
Deutsche Bank Research maintained a "Hold" rating for Novartis stock with a 120 Swiss Francs price target, based on weekly prescription data.
finanzen.ch · Sep 29, 2026
Aktien Schweiz: Fester dank Novartis und Nestlé, Roche fallen ab
The Swiss stock market rose, led by strong performances from Novartis and Nestlé, while tech stocks and Roche declined amid geopolitical concerns and tech sector news.
de.marketscreener.com · Sep 28, 2026
Novartis eröffnet neue Niederlassung in München
Novartis opened a new office in Munich, making it a key hub and sparking discussions on pharmaceutical innovation, policy challenges, and the need for a more supportive regulatory environment in Germany.
vc-magazin.de · Sep 24, 2026
US-Gericht weist Klage gegen Novartis wegen Entresto-Generika ab
A US federal court dismissed a class-action lawsuit against Novartis, ruling that the company did not unlawfully delay generic competition for its heart failure drug, Entresto.
de.marketscreener.com · Sep 23, 2026

Novartis Deutschland is a B2B company in the Pharmaceutical Manufacturing industry, headquartered in Nuremberg, Bavaria, Germany.

Novartis Deutschland has 251–1,000 employees.

Novartis Deutschland's revenue is $59.7M – $472M (Tamtam estimate).

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.